Chapter Two

‘Enterprise Architecture for Digital Business’ Outlines Why and How to Modernize IT for a Digital-First World

Retrieved on: 
Mardi, juillet 26, 2022
Data Management, Technology, Entertainment, Books, Security, Telecommunications, Apps, Applications, Artificial Intelligence, Networks, Internet, Mobile, Wireless, Chapter Two, XAML, Education, Chapter Five, Thought, Foundation, Apple Books, Digital, Industry, Twitter, Network, Chapter One, Site reliability engineering, Telemetry, Barnes & Noble, Powell, Software, FFIV, Patent, ANSI, NASDAQ, Chapter Three, CTO, Chapter Four, Organization, Adoption, Architecture, Facebook, Ageing, EVP, SRE, Technology, Chapter Seven, Transport, LinkedIn, Life, IndieBound, Chapter Six, Automation, Internet, Book, TOGAF, CADD, Creative industries, Management, Online shopping, Video game console, Cryptocurrency, Autodesk, Engineering, F5, Amazon

To progress further in their digital transformation journeys, companies will require a new approach to enterprise architecture that is purpose-built for the digital economy.

Key Points: 
  • To progress further in their digital transformation journeys, companies will require a new approach to enterprise architecture that is purpose-built for the digital economy.
  • The need for a new digital enterprise architecture is both inevitable and urgent, said Geng Lin, EVP and CTO, F5.
  • The book outlines an architecture framework for transitioning IT to operate as a digital business, support innovation, and address todays biggest IT challenges.
  • Chapter 1 discusses the changes to existing enterprise architecture needed to infuse the capabilities required by a digital business.

One in Two Students Have Personally Witnessed Cheating: 2022 Student Wellbeing Study Reveals State of Academic Misconduct in Canada

Retrieved on: 
Mercredi, juin 22, 2022
Student, Population, List of life sciences, COVID-19, Subject, Chapter Two, Faculty, Medicine, Memorial University of Newfoundland, Provost, Optimism, Interview, Academic integrity, University, Plagiarism, United Kingdom, Assessment, Life, Tutoring, Management

Another student said, "Professors often expect students to be cheating in these remote study environments, and purposely increase difficulty of tests and exams.

Key Points: 
  • Another student said, "Professors often expect students to be cheating in these remote study environments, and purposely increase difficulty of tests and exams.
  • "Students feel cheating has gotten easier, yet combatting academic misconduct is increasingly more difficult in a virtual environment.
  • This chapter on Academic Integrity, Cheating, & Assessment was a new addition to the Canadian Student Wellbeing Study in an effort to understand student thoughts and feelings on the effects of academic misconduct and dishonesty.
  • Studiosity partners with universities to provide online study support, anytime, anywhere to over 1.6 million students in Canada, Australia, and the United Kingdom.

New Study Uncovers Untapped Potential for Legal Departments to Positively Impact Revenue Growth and Operational Efficiency

Retrieved on: 
Mardi, juin 21, 2022
Law, Time, Contract, DEI, Chapter Two, Attention, Intelligence, Perception, Technology, Artificial intelligence, Compliance, Efficiency, LinkedIn, CLM, Growth, News, ELR, Twitter, HR, Origanum onites, GLOBE, Risk management, Public relations, Management

The study helps corporate legal departments understand their brand image through the eyes of their internal clients so they can improve working relationships, accelerate legal workflows and more effectively impact topline revenue and operational efficiency.

Key Points: 
  • The study helps corporate legal departments understand their brand image through the eyes of their internal clients so they can improve working relationships, accelerate legal workflows and more effectively impact topline revenue and operational efficiency.
  • The biggest opportunity to impact revenue generation relies on a strong link to Sales, as nearly seven in 10 (68%) legal respondents believe they help Sales effectively close deals and generate revenue.
  • Automated, AI-driven contract lifecycle management (CLM) is a major opportunity for legal departments to support the speed and growth of their business.
  • Onit is a global leader in artificial intelligence platforms and enterprise workflow solutions for legal, compliance, sales, IT, HR and finance departments.

Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials for 280 Deals Signed Between the World's Pharma and Biotechnology Companies - ResearchAndMarkets.com

Retrieved on: 
Lundi, juin 13, 2022
Health, General Health, Orientation, Directory, Research, Biotechnology, Players, Hyperlink, Contract, Chapter Three, Chapter Five, Chapter Four, Chapter Two, Finance, Technology, Review, Chapter Six, SEC, Pharmaceutical industry

The Global Orphan Diseases Partnering 2010-2022 report provides comprehensive access to available deals and contract documents for over 280 orphan diseases deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Key Points: 
  • The Global Orphan Diseases Partnering 2010-2022 report provides comprehensive access to available deals and contract documents for over 280 orphan diseases deals signed between the world's pharmaceutical and biotechnology companies since 2010.
  • The report takes readers through the comprehensive Orphan Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Orphan Diseases deals.
  • Chapter 6 provides a comprehensive directory of all Orphan Diseases partnering deals by specific Orphan Diseases target announced since 2010.
  • Global Orphan Diseases Partnering 2010 to 2022 includes:
    In Global Orphan Diseases Partnering 2010 to 2022, available deals and contracts are listed by:

Global Ophthalmics Partnering Analysis Report 2014-2022: Trends, Players and Financials for 550+ Deals - ResearchAndMarkets.com

Retrieved on: 
Lundi, juin 13, 2022
Health, General Health, Orientation, Directory, Research, Biotechnology, Players, Hyperlink, Ocular hypertension, Diabetic retinopathy, Contract, Chapter Three, Visual impairment, Chapter Five, Chapter Four, Chapter Two, Cataract, Finance, A-Z, Technology, Review, Conjunctivitis, Chapter Six, SEC, Uveitis, Pharmaceutical industry, Music, Sales, Ophthalmic pathology, Glaucoma

The "Global Ophthalmics Partnering 2014-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ophthalmics Partnering 2014-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Ophthalmics Partnering 2014-2022 report provides comprehensive access to available deals and contract documents for over 550 ophthalmics deals signed between the world's pharmaceutical and biotechnology companies since 2014.
  • In addition, a comprehensive appendix is provided with each report of all Ophthalmics partnering deals signed and announced since 2014.
  • Global Ophthalmics Partnering 2014 to 2022 includes:
    In Global Ophthalmics Partnering 2014 to 2022, available deals and contracts are listed by:

Locust Bean Gum Market Forecasts and Opportunities Report 2021 - Trends, Outlook and Implications Across COVID Recovery Cases to 2028 - ResearchAndMarkets.com

Retrieved on: 
Mardi, juin 7, 2022
Retail, Other Natural Resources, Manufacturing, Natural Resources, Other Manufacturing, Food, Beverage, Chapter Nine, COVID, Locust bean gum, Contract, Chapter Seven, Chapter Five, Chapter Four, Solution, Chapter Two, Budget, Growth, Chapter Six, COVID-19, Industry, Chapter Eight, SWOT, View, Chapter Ten, Legume

Introduction to Locust Bean Gum Markets, 2021

Key Points: 
  • Introduction to Locust Bean Gum Markets, 2021
    The global Locust Bean Gum market analysis report is a comprehensive study detailing the market analysis during 2021.
  • The focused Locust Bean Gum market report emphasizes Locust Bean Gum industry size, key events, Locust Bean Gum market statistics, and key factors prominent in the Locust Bean Gum industry forecast and leading companies.
  • Locust Bean Gum market growth factors, restraints, opportunities and market trends
    Key factors shaping the future of Locust Bean Gum markets, driving factors, short term, and long term challenges, and potential market opportunities ahead of market players and the factors affecting the Locust Bean Gum market outlook are provided in detail.
  • Chapter 2 presents Locust Bean Gum market trends, insights, challenges, niche opportunities across the industry
    Chapter 4 analyzes and forecasts the leading Locust Bean Gum market types, applications, and countries
    Chapter 5 presents North America Locust Bean Gum Market analysis and outlook to 2028 (Countries: US, Canada, Mexico)
    Chapter 6 presents Europe Locust Bean Gum Market Analysis and Outlook to 2028 (Countries: Germany, UK, France, Spain, Italy, Others)
    Chapter 7 presents Asia Pacific Locust Bean Gum Market Size Outlook to 2028 (Countries: China, Japan, India, South Korea, Others)
    Chapter 8 presents Latin America Locust Bean Gum Market Analysis and Outlook to 2028 (Countries: Brazil, Argentina, Chile, Others)
    Chapter 9 presents the Middle East and Africa Locust Bean Gum Market Analysis and Outlook to 2028 (Countries: Saudi Arabia, UAE, Middle East, South Africa, and Other Africa)
    Chapter 10 details the company profiles, their SWOT profiles, business analysis, financials, and other developments
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005823/en/

GENFIT: May 25, 2022 Combined Shareholders Meeting results

Retrieved on: 
Mercredi, mai 25, 2022
U.S. Securities and Exchange Commission, Roger W. Jones Award for Executive Leadership, Company, History, Private Securities Litigation Reform Act, NASH, FRANCE, Nasdaq, Doctor of Philosophy, Director, Patient, AMF, PBC, Review, Chapter Two, Research, United Kingdom, Cholangiocarcinoma, Industry, Partnership, Liver disease, Primary biliary cholangitis, Board, Safety, Biomarker, Board of directors, Loos, Cirrhosis, LabCorp, SEC, Acquisition, Chronic liver disease, Annual report, Management, Pharmaceutical industry, Euronext, Pharmacovigilance, ACLF, Ipsen

The quorum on first convening amounted to 25.16% and shareholders approved all of the resolutions submitted by the Board of Directors.

Key Points: 
  • The quorum on first convening amounted to 25.16% and shareholders approved all of the resolutions submitted by the Board of Directors.
  • Jean-Franois Mouney, Chairman of GENFITs Board of Directors, commented: I would like to thank all of our shareholders who participated in this Combined Shareholders Meeting.
  • This appointment is in keeping with the long-term strategic partnership agreement signed with Ipsen at the end of 2021.
  • In ACLF, a Phase 1 clinical program with nitazoxanide has been initiated with data expected as early as the third quarter 2022.

GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)

Retrieved on: 
Mercredi, mai 11, 2022
Company, History, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, NASH, FRANCE, Nasdaq, Patient, AMF, PBC, Review, Chapter Two, Research, United Kingdom, Cholangiocarcinoma, Industry, Partnership, Liver disease, Primary biliary cholangitis, Safety, Biomarker, Loos, IFRS, Cirrhosis, LabCorp, SEC, Acquisition, Chronic liver disease, Annual report, Online gambling, Cryptocurrency, Security (finance), Pharmaceutical industry, Euronext, VAT, ACLF, Ipsen

Furthermore, to underscore the long-term commitment represented by this partnership, Ipsen purchased newly issued GENFIT equity representing 8% post-issuance through a 28.0 million investment in GENFIT.

Key Points: 
  • Furthermore, to underscore the long-term commitment represented by this partnership, Ipsen purchased newly issued GENFIT equity representing 8% post-issuance through a 28.0 million investment in GENFIT.
  • Revenues for the first three months of 2022 amounted to 3.895 million compared to 1 thousand for the same period in 2021.
  • Revenues for the first three months of 2022 mainly came from the partial recognition of this amount corresponding to this period.
  • In ACLF, a Phase 1 clinical program with nitazoxanide has been initiated with data expected as early as the third quarter 2022.

GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022

Retrieved on: 
Vendredi, avril 29, 2022
U.S. Securities and Exchange Commission, AMF, FRANCE, Statute, Patient, Nasdaq, Chapter Two, PBC, Liver disease, Investor, The Annual, Cirrhosis, Private Securities Litigation Reform Act, Chronic liver disease, Loos, United Kingdom, History, LabCorp, Biomarker, Company, Mission statement, Acquisition, Annual report, Research, Statutory auditor, Board, NASH, Industry, SEC, Review, Primary biliary cholangitis, Cholangiocarcinoma, Safety, Online gambling, Pharmaceutical industry, Euronext, ACLF

The 2021 Registration Document is also available on the AMFs website: www.amf-france.org and the Annual Report on Form 20-F is available on the website of the SEC ( www.sec.gov ).

Key Points: 
  • The 2021 Registration Document is also available on the AMFs website: www.amf-france.org and the Annual Report on Form 20-F is available on the website of the SEC ( www.sec.gov ).
  • Documents for the Annual Combined Shareholders Meeting on May 25, 2022 are available to shareholders in accordance with existing regulations, and can be found on the Companys website, in the Investors and Media section ( https://ir.genfit.com/financial-information/shareholders-meeting ).
  • GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs.
  • In 2021, GENFIT signed an exclusive licensing agreement with IPSEN to develop, manufacture and commercialize elafibranor in PBC and other indications.

GENFIT Annual Combined General Meeting of May 25, 2022 — Availability of Preparatory Documents

Retrieved on: 
Mercredi, avril 20, 2022
Nasdaq, Liver disease, Pharmacy, Internet, Cholangiocarcinoma, Primary biliary cholangitis, LabCorp, U.S. Securities and Exchange Commission, PARC, Documentation, Chapter Two, Research, Cirrhosis, Annual report, NASH, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Private Securities Litigation Reform Act, Patient, Loos, Biomarker, Bulletin, PBC, Review, Company, United Kingdom, Chronic liver disease, FRANCE, SEC, Faculty, History, Investor, Safety, Industry, Acquisition, AMF, Pharmaceutical industry, ACLF, Euronext

For this 2022 Combined General Meeting, the Company will allow shareholders to send their voting instructions via Internet through the VOTACCESS platform.

Key Points: 
  • For this 2022 Combined General Meeting, the Company will allow shareholders to send their voting instructions via Internet through the VOTACCESS platform.
  • GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs.
  • GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades.
  • In 2021, GENFIT signed an exclusive licensing agreement with IPSEN to develop, manufacture and commercialize elafibranor in PBC and other indications.